Quanome Technologies, Inc.

Quanome Technologies, Inc.(QNME)股票分析

$0.383

+0.046 (+11.96%)收盤時

Loading chart…
最高
0.386
開盤
0.360
成交量加權均價
0.38
成交量
159.27K
市值
—
最低
0.360
成交金額
59.95K
企業價值/稅息折舊攤銷前利潤(TTM)
0.00

Lakeside Holding Limited is a holding company. The Company, through its subsidiary, Hupan Pharmaceutical (Hubei) Co., Ltd, is a medical injection and pharmaceutical distributor. It procures products from manufacturers, stores the products at designated warehouses, and distributes them to hospitals, distributors and other healthcare providers, primarily through agents.

AI 分析 of Quanome Technologies, Inc. (QNME)

賣出

Given the current price of 0.38, the stock's RSI is at 37.591, indicating it is oversold. However, the forward P/E ratio is 0, and the gross margin has dropped to 7.96%, which raises concerns about profitability. The stock has seen a 20-day change of -48.35%, suggesting significant downward momentum. Therefore, it is advisable to sell rather than buy at this time.

估值指標

Quanome Technologies, Inc.(QNME)目前預期本益比為 0.00,5 年平均預期本益比為 。

預期本益比

5 年均值 P/E
目前P/E
0.00

預期 EV/EBITDA

5 年均值 EV/EBITDA
目前EV/EBITDA
0.00

預期股價營收比

5 年均值 P/S
目前P/S
0.00

QNME 常見問題 —— 由 Alphio AI 解答

Lakeside Holding Limited is a holding company. The Company, through its subsidiary, Hupan Pharmaceutical (Hubei) Co., Ltd, is a medical injection and pharmaceutical distributor. It procures products from manufacturers, stores the products at designated warehouses, and distributes them to hospitals, distributors and other healthcare providers, primarily through agents.

Given the current price of 0.38, the stock's RSI is at 37.591, indicating it is oversold. However, the forward P/E ratio is 0, and the gross margin has dropped to 7.96%, which raises concerns about profitability. The stock has seen a 20-day change of -48.35%, suggesting significant downward momentum. Therefore, it is advisable to sell rather than buy at this time.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易